These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1022953)

  • 21. [Late-occurring cutaneous vasculitis after successful treatment of diffuse lepromatous leprosy: Lucio's phenomenon].
    Fenniche S; Benmously R; Sfia M; Daoud L; Debbiche A; Ben Ayed M; Mokhtar I
    Med Trop (Mars); 2007 Feb; 67(1):65-8. PubMed ID: 17506277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Electrogustometry in Hansen's disease (study of 225 cases).
    Rathi SS; Chaturvedi VN; Raizada RM; Jain SK
    Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):252-5. PubMed ID: 3722964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A study of blood ascorbic acid in leprosy.
    Sinha SN; Gupta SC; Bajaj AK; Singh PA; Kumar P
    Int J Lepr Other Mycobact Dis; 1984 Jun; 52(2):159-62. PubMed ID: 6539308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unexplained delayed nerve impairment in leprosy after treatment.
    Rosenberg NR; Faber WR; Vermeulen M
    Lepr Rev; 2003 Dec; 74(4):357-65. PubMed ID: 14750581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dapsone resistant leprosy, the western Kenya experience.
    Orege PA; Owili DM
    Trop Geogr Med; 1985 Jun; 37(2):139-42. PubMed ID: 4035777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of single dose (1500 mg) rifampicin on infectivity of patients with lepromatous leprosy.
    Girdhar BK; Sreevatsa ; Desikan KV
    Lepr India; 1980 Jul; 52(3):359-65. PubMed ID: 7206633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New lesions after MDT in PB and MB leprosy: a report of 28 cases.
    Kar HK; Sharma P
    Indian J Lepr; 2008; 80(3):247-55. PubMed ID: 19432355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral zinc as an adjunct to dapsone in lepromatous leprosy.
    Mathur NK; Bumb RA; Mangal HN; Sharma ML
    Int J Lepr Other Mycobact Dis; 1984 Sep; 52(3):331-8. PubMed ID: 6541200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India.
    Pocaterra L; Jain S; Reddy R; Muzaffarullah S; Torres O; Suneetha S; Lockwood DN
    Am J Trop Med Hyg; 2006 May; 74(5):868-79. PubMed ID: 16687695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemotherapeutic trials in leprosy. 2. Comparative trial of dapsone plus ditophal (Etisul) and dapsone alone in the treatment of lepromatous leprosy.
    Waters MF; Pettit JH
    Int J Lepr; 1965; 33(3):280-96. PubMed ID: 5322767
    [No Abstract]   [Full Text] [Related]  

  • 31. Intermittent rifampicin therapy in lepromatous leprosy.
    Girdhar BK; Sreevatsa ; Desikan KV
    Lepr India; 1980 Jan; 52(1):89-96. PubMed ID: 6991816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A controlled trial to compare the therapeutic effects of dapsone in combination with daily or once-monthly rifampin in patients with lepromatous leprosy.
    Opromolla DV; Tonello CJ; McDougall AC; Yawalkar SJ
    Int J Lepr Other Mycobact Dis; 1981 Dec; 49(4):393-7. PubMed ID: 7042603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A field trial among leprosy patients in Nigeria with depot injections of dapsone and monoacetyldapsone.
    Pieters FA; Woonink F; Zuidema J
    Int J Lepr Other Mycobact Dis; 1988 Mar; 56(1):10-20. PubMed ID: 3373080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
    Becx-Bleumink M; Berhe D
    Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):173-84. PubMed ID: 1522359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical trial with clofazimine in leprosy.
    Ganapati R; Dongre VV
    Lepr India; 1976 Oct; 48(4 Suppl):703-8. PubMed ID: 1026807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective study on the relationship between intensive bactericidal therapy and leprosy reactions.
    Groenen G; Janssens L; Kayembe T; Nollet E; Coussens L; Pattyn SR
    Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):236-44. PubMed ID: 3722962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The frequency of the appearance of perforating foot ulcers in patients with Hansen's disease as a function of treatment with disulone alone or with polychemotherapy].
    Mane I; Grauwin MY; Cartel JL
    Acta Leprol; 1995; 9(3):127-31. PubMed ID: 7631583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relapse rate and incidence of dapsone resistance in lepromatous leprosy patients in Addis Ababa: risk factors and effect of short-term supplementary treatment.
    Warndorff van Diepen T; Mengistu G
    Int J Lepr Other Mycobact Dis; 1985 Jun; 53(2):189-97. PubMed ID: 2410520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relationship of dapsone (DDS) therapy to erythema nodosum leprosum. Is it direct or indirect?
    Waters MF; Helmy HS
    Lepr Rev; 1974 Dec; 45(4):299-307. PubMed ID: 4613978
    [No Abstract]   [Full Text] [Related]  

  • 40. Reactive episodes in borderline lepromatous leprosy--a case report.
    Acharya PV; Gupta OP; Nigam SP; Agrawal RV
    Lepr India; 1976 Jul; 48(3):311-3. PubMed ID: 1022972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.